Generic Name and Formulations:
Ceftriaxone sodium 500mg, 1g; IM or IV inj; sodium content 3.6mEq/g.
Various generic manufacturers
Indications for Ceftriaxone:
Susceptible bacterial septicemia, acute bacterial otitis media, lower respiratory tract, UTIs, skin and skin structure, bone and joint, pelvic inflammatory disease (PID), intraabdominal infections, meningitis, uncomplicated gonorrhea. Surgical prophylaxis.
1–2g IM or IV once daily or in 2 equally divided doses; max 4g/day. Gonorrhea: 250mg IM once. Surgery: a single dose of 1g IV ½–2 hours pre-op.
50–75mg/kg per day in equally divided doses every 12hrs; max 2g/day. Skin and skin structures: may give once daily or in 2 equally divided doses every 12hrs; max 2g/day. Meningitis: 100mg/kg (max 4g) for 1 dose, then 100mg/kg per day (max 4g/day) once daily or in 2 equally divided doses every 12hrs for 7–14 days. Otitis media: 50mg/kg (max 1g) IM once.
Hyperbilirubinemic or premature neonates. Concomitant calcium-containing IV solutions or products in neonates. Ceftriaxone solutions containing lidocaine for IV administration.
Penicillin or other beta-lactam allergy. Discontinue if urolithiasis, oliguria, renal or gallbladder sonographic abnormalities, signs or symptoms occur. Renal failure: monitor; decrease dose if drug accumulation occurs. Chronic hepatic disease or malnutrition (impaired Vit. K synthesis or storage): monitor prothrombin time. Both hepatic and significant renal impairment: usual max 2g/day. GI disease (esp. colitis). Ensure adequate hydration. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. Increase risk of bleeding with concomitant Vit. K antagonists. May be potentiated by probenecid. Precipitation can form with calcium-containing solutions; avoid. May cause false (+) Clinitest or Coomb's test.
Local reactions, hematologic effects (eg, eosinophilia), rash, diarrhea, elevated liver enzymes; rare: hemolytic anemia, allergic pneumonitis, seizures, anaphylaxis, pancreatitis.
Formerly known under the brand name Rocephin.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Risk of Developing Multiple Sclerosis After HPV Vaccination
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid-Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics